Keryx Biopharmaceuticals (NASDAQ:KERX)
CAPS Rating:
A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.
RSS Headlines
Fool UK
Recs
sold in Real Life at 3.82, now flipping short
yikes!
it is OK to miss a run or two, but making a mistake on a short in real life can be deadly. take note!